☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Regenxbio
REGENXBIO Reports the Clinical Trial Results for RGX-121 to Treat Mucopolysaccharidosis Type II (MPS II)
February 8, 2024
REGENXBIO’s RGX-121 Receives the US FDA’s RMAT Designation for the Treatment of Hunter Syndrome
May 24, 2023
REGENXBIO Reports Interim Results of RGX-314 in the P-II Bridging Study for Wet Age-Related Macular Degeneration
February 13, 2023
REGENXBIO Initiates P-I/II Trial of RGX-202 for the Treatment of Duchenne Muscular Dystrophy
January 24, 2023
REGENXBIO Presents Interim P-II (ALTITUDE) Trial Results of RGX-314 for Diabetic Retinopathy Using Suprachoroidal Delivery at 55th...
November 3, 2022
REGENXBIO Reports Interim P-II (AAVIATE) and P-I/IIa Long-term Follow-up Study of RGX-314 for Wet AMD
October 4, 2022
Load more...
Back to Home
Modal title
×
Modal body text goes here.